Previous literature has shown that the endogenous CB1R agonist, AEA, that is elevated in schizophrenia [66] modulates synaptic plasticity by inhibiting glutamatergic NMDA Ca2 + flux in the hippocampus, critical for modulating the relative strength and efficacy between synaptic connections [67]. This evidence concerns the gene CNR1 and schizophrenia.